-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Knowledge Translation
Who and What is the Dementia Envoy? (WDC / Department of Health)
Summary The Prime Minister has appointed David Mayhew as the latest Dementia Envoy. Dennis Gillings was the former World Dementia Envoy. “The envoy works with countries, corporations and leaders from around the world, sharing expertise and promoting research and support … Continue reading →
Posted in Alzheimer’s Research UK, Charitable Bodies, Commissioning, Department of Health, For Researchers (mostly), In the News, International, Mental Health, Models of Dementia Care, National, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Academia-Industry Partnerships, Alzheimer’s Research UK (ARUK), British Prime Minister's Office, Challenge on Dementia (David Cameron), Collaborative Projects, Cross-Sector Partnerships, Data Sharing, David Cameron, David Mayhew CBE: Former Chairman of JP Morgan Cazenove, David Mayhew CBE: Vice Chairman of JP Morgan’s Global Investment Bank, David Mayhew CBE: Wellcome Trust Investment Committee, David Mayhew: Chairman of Alzheimer’s Research UK, David Mayhew: Dementia Envoy (2016-), Dementia Challenge, Dementia Consortium, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Friends, Dementia Innovation, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Dennis Gillings: Former World Dementia Envoy, Department of Health Dementia Challenge, GAAD: Global Action Against Dementia, Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Envoy for Dementia Innovation, Global Outlook, Global Social Investment for Dementia, Government Research Funding, International Collaborations, International Programmes, JP Morgan, Knowledge Translation, Leadership, Partnership, Partnership and Collaboration, Partnership Working, Prime Minister's Challenge on Dementia, Prime Minister's Office, Prime Minister’s Dementia Challenge, Research and Innovation, Rt Hon Jeremy Hunt MP: Former Secretary of State for Health, WDC: World Dementia Council, World Alzheimer Report 2014, World Dementia Council, World Dementia Envoy
|
Leave a comment
Public Health England’s Research and Innovation Strategy (PHE / NHS IQ)
Summary Public Health England (PHE) have released their strategy for research, development and innovation, following a consultation. The set of seven PHE priorities have been resolved across five broader high level strategic constructs. Topic headings in this report comprise: The … Continue reading →
Posted in Commissioning, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Integrated Care, Management of Condition, National, Non-Pharmacological Treatments, Patient Care Pathway, Public Health England, Quick Insights, Standards, Statistics, UK, Universal Interest
|
Tagged Academic Health Science Networks (AHSNs), Academic Public Health Research Support Network, Andrew Lambe: NHS IQ's Knowledge and Intelligence Team, ‘Social Science Shaping Society, Best Research for Best Health, Better Knowledge Better Care (BKBC), Birmingham University, BKBC: Better Knowledge Better Care (NHS IQ), Cambridge MRC Biostatistics Unit, Cambridge Veterinary School, Childhood Obesity, Cigarette Smoking, CLAHRC: Collaboration for Leadership in Applied Health Research and Care, Clinical Practice Research Datalink (CPRD), Clinical Research Networks (CRNs), Collaborations for Leadership in Applied Health Research and Care (CLAHRCs), Davenport on KM, Dementia Risk Factors, Dementia Risk Prevention, Dementia Risk Reduction, Empire Building, Epidemiology, Epidemiology and Statistics, Evidence Into Action (PHE), Exeter University, Global Burden of Disease (GBD), Health and Social Care Information Centre (HSCIC), Health and Wellbeing, Health Equity, Health Inequalities, Health Protection Research Units (HPRUs), Healthy Life Expectancy, Healthy Lifestyles, HEE Research and Innovation Strategy, Imperial College London, Imperial College NHS Trust, Inequality in Healthy Life Expectancy, Institute of Food Research, Integrated Knowledge Translation (IKT), Irresponsible Drinking, JLA PSP: James Lind Alliance Priority-Setting Partnership, Joanne Loughlin-Ridley: NHS IQ’s Knowledge and Intelligence Team, Kings College London, Knowledge Conversion, Knowledge Cycle, Knowledge Management (KM), Knowledge Networks, Knowledge Translation, Knowledge Translation Theory, Knowledge Workers, Learning and Clinical Networks, Learning Culture, Lifestyle Risk Factors, Living Longer: Reducing Avoidable Premature Mortality, Living Well for Longer, Local Public Health, Local Public Health Services, Local Public Health System Functions, London School of Hygiene and Tropical Medicine, Midlife Obesity, Modifiable Risk Factors, National Prevention Research Initiative (NPRI), Newcastle University, NHS England’s Five Year Forward View, NHS Five Year Forward View (5YFV), NHS Improving Quality (NHS IQ), NHS IQ, NHS IQ’s Knowledge and Intelligence Team, NHS Preventative Services, NIHR Health Informatics Collaborative (NIHR HIC), NIHR Health Protection Research Unit (HPRU) Initiative, NIHR Health Protection Research Units, NIHR HPRU: NIHR Health Protection Research Unit, NIHR HPRUs, NIHR School for Primary Care Research, NIHR School for Public Health Research, NIHR School for Public Health Research (SPHR), NIHR School for Social Care Research, NIHR SPHR: NIHR School for Public Health Research, NOCRI: NIHR Office for Coordination of Clinical Research Infrastructure, NWL Academic Health Science Network, Obesity, Obesity Epidemic, Obesity Time-Bomb, Organisational Knowledge Management, PHE Intervention Evaluation Process, PHE Knowledge Management Framework, PHE Publication Standard Process, PHE R&D Group, PHE Research and Innovation Strategy, PHE Research and Innovation Strategy: Priority Five. Communication, PHE Research and Innovation Strategy: Priority Four. Innovation, PHE Research and Innovation Strategy: Priority One. Knowledge, PHE Research and Innovation Strategy: Priority Three. Capacity, PHE Research and Innovation Strategy: Priority Two. Infrastructure, PHE: Public Health England, PHE’s Knowledge Strategy, PHE’s Research Strategy, Preventable Mortality, Preventative Care, Preventative Services, Prevention of Tobacco Related Diseases, Problem Drinking, Protecting and Improving the Nation’s Health (PHE), Public Health, Public Health England (PHE), Public Health England: Research and Innovation Strategy (2015), Public Health Knowledge Cycle, Public Health Outcomes Framework, Public Health Workforce Strategy, Research and Innovation, Research Changes Lives, Research Networks, Research Priorities and Networks, Research Translation and Innovation, Smoking-Related Mortality, Social Deprivation, Social Determinants of Health, Social Determinants of Health Inequalities, Social Economic and Environmental Determinant, Social Epidemiology, Social Inequality, Supporting Research and Innovation, Translational Research, UKCRC Centres of Excellence in Public Health, UKCRC: UK Clinical Research Collaboration, University College London, University College London London, University of Bristol, University of East Anglia, University of Liverpool, University of Liverpool: Liverpool School of Tropical Medicine, University of Oxford, University of Oxford Animal and Plant Health Agency, University of the West of England, Wellbeing, Wellcome Sanger Institute, Wellness and Resilience
|
Leave a comment
Challenges in Developing Disease-Modifying Treatments for Dementia (Department of Health)
Summary Raj Long, the Senior Regulatory Officer at the Bill & Melinda Gates Foundation, explores the problems in developing treatments for dementia. The independent “Finding a Path for the Cure for Dementia” report is a contribution to the G8 Dementia … Continue reading →
Posted in Charitable Bodies, Commissioning, Department of Health, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest
|
Tagged Academia-Industry Partnerships, Academic Research, AIFA: Italian Medicines Agency, Attrition Analysis, BfArM: Federal Institute of Drugs and Medical Devices, BfArM: Federal Institute of Drugs and Medical Devices (Germany), Bill and Melinda Gates Foundation, Biopharmaceutical Companies, Burden of Dementia, Canada, CEOi: Global CEO Initiative on Alzheimer’s Disease, Challenge on Dementia (David Cameron), Charitable Funding, Clinical Trial Efficiencies, Collaboration, Collaborative Projects, Composite End Points, Consistent Global Development Pathways, Cross-Sector Partnerships, CTEG: Clinical and Technical Expert Group, Danish Health and Medicines Authority, Data Sharing, Dementia Challenge, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Denmark, Department of Health Dementia Challenge, Diagnosis and Referral, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DKMA: Danish Health and Medicines Authority, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, Eli Lilly Inc., Eli Lilly’s UK Dementia Research Centre, EMA: European Medicines Agency, European Medicines Agency, European Union, FIH: First in Humans, Financial Incentives, First Global Ministerial Conference on Global Action Against Dementia, Food and Drug Administration, G20 Countries, G7 Countries, G8 Dementia Summit: Global Action Against Dementia, G8 Summit, Gaps in the Basic Science, Germany, Global Alzheimer’s and Dementia Action Alliance (GADAA), Global Envoy for Dementia Innovation, Global Leadership, Global Outlook, Global Social Investment for Dementia, Government Research Funding, Health Canada, IAP Steering Committee, IDAP Steering Committee, IDAP: International Dementia Advisory Platform, IFPMA: International Federation of Pharmaceutical Manufacturers & Associations, Incentives and Investment, Incentives for Drug Development, Independent Safety Review Committee, Integrated Development Pathway, International Collaborations, International Dementia Advisory Platform (IDAP), International Dementia Research Inventories, International Programmes, Italian Medicines Agency, Italy, Japan, Japan: Pharmaceuticals and Medical Devices (Japan), Knowledge Translation, MEB: Medicines Evaluations Board, Medicines and Healthcare Products Regulatory Agency, Medicines Evaluation Board Netherlands, MHRA: Medicines and Healthcare Products Regulatory Agency, Modelling and Extrapolation, Multilateral Cooperation, Multilateral Regulator Cooperation, Netherlands, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurological Research, OHE: Office of Health Economics, Open Access Databases, Open Access Knowledge Resources, Open Access Research, Open Science, Organisation for Economic Co-operation and Development (OECD), Organisation for Economic Co-operation and Development (OECD) Countries, Organisation for Economic Cooperation and Development, Partnership, Partnership and Collaboration, Partnership Working, Patient Viewpoint, Philanthropic Funding, Pipeline Databases, PMDA: Pharmaceutical and Medicines Devices Agency, Public-Private Partnership (PPP), Quantifiable Reproducible Outcome Measures, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Reasons for Termination of Trials, Regulator Perspectives, Regulatory Agencies, Regulatory Experts, Research and Developers’ Status Quo, Research and Development, Research and Innovation, Research Commitment, Research Funding, Research Status Quo, Resource and Incentives, Risk Benefit Balance, Standardisation and Validation of Cognitive Endpoints, Swiss Medic, Switzerland, United States, WDC: World Dementia Council, World Dementia Council, World Health Organisation (WHO)
|
Leave a comment
Announcements From WHO’s First Ministerial Conference on Global Action Against Dementia Conference (Dementia Challenge / Department of Health / World Dementia Council / WHO / GAAD)
Summary Health Secretary Jeremy Hunt has announced a $100 million Dementia Discovery Fund at the World Health Organisation’s First Ministerial Conference on Global Action Against Dementia Conference. The Dementia Discovery Fund will be used to finance dementia research with the … Continue reading →
Posted in Acute Hospitals, Charitable Bodies, Commissioning, Community Care, Department of Health, Diagnosis, End of Life Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, National, NIHR, Non-Pharmacological Treatments, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, Statistics, UK, Universal Interest, World Health Organization (WHO)
|
Tagged $100m Dementia Discovery Fund, Ageing and Dementia, Ageing and Society, Ageing Population, Alzheimer's Research UK, Alzheimer’s Research UK (ARUK), ARUK: Alzheimer’s Research UK, Awareness Raising, Big Pharma, Biogen, Biopharmaceutical Companies, Burden of Dementia, Challenge on Dementia (David Cameron), Collaboration, Collaborative Projects, Cross-Sector Partnerships, Dementia Challenge, Dementia Diagnosis, Dementia Discovery Fund, Dementia Research, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Margaret Chan: WHO Director-General, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, Eli Lilly Inc., Eli Lilly’s UK Dementia Research Centre, First Global Ministerial Conference on Global Action Against Dementia, First WHO Ministerial Conference on Global Action Against Dementia, Former Health Secretary Jeremy Hunt, G8 Dementia Summit: Global Action Against Dementia, GlaxoSmithKline, Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Ministerial Conference on Global Action Against Dementia (WHO), Global Outlook, Government Research Funding, Human Rights, International Collaborations, International Programmes, Johnson & Johnson, JP Morgan, Knowledge Translation, Leadership, Lilly, Ms. Cathrin Petty: JP Morgan, OECD, Organisation for Economic Co-operation and Development (OECD), Organisation for Economic Co-operation and Development (OECD) Countries, Partnership, Partnership and Collaboration, Partnership Working, Pfizer, Pfizer Inc., Pharmaceutical Industry, Prime Minister’s Dementia Challenge, Quality of Care, Quality of Care and Support, Quality of Care for People With Dementia, Reducing Stigma, Research and Development, Research and Innovation, Research Commitment, Research Funding, Rt Hon Jeremy Hunt MP: Former Secretary of State for Health, WDC: World Dementia Council, World Dementia Council, World Health Organisation (WHO)
|
Leave a comment
Emerging Leaders In Dementia: Communiqué for the First WHO Ministerial Conference on Global Action Against Dementia (World Dementia Council)
Summary A group of “young leaders in dementia” will take part in the First Global Ministerial Conference on Global Action Against Dementia, which is to be hosted by the World Health Organisation (WHO) in Geneva on March 16th – 17th … Continue reading →
Posted in Acute Hospitals, Assistive Technology, Charitable Bodies, Commissioning, Community Care, Department of Health, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest, World Health Organization (WHO)
|
Tagged Ageing and Dementia, Ageing and Society, Ageing Population, American Association for the Advancement of Sciences, Awareness Raising, Burden of Dementia, Care Standards, Care Standards in Hospitals, Carer Experience, Carer's Experience of Dementia, Carers’ Experiences of the Dementia Journey, Center for Public Engagement with Science and Technology (the American Association for the Advancement of Sciences), Challenge on Dementia (David Cameron), Collaboration, Collaborative Projects, Cross Sector Working, Cross-Sector Partnerships, Dementia Challenge, Dementia Diagnosis, Dementia Grand Challenge Proposal (WDC or G7 Sponsorship for Jumpstarting Radical Breakthroughs in Prevention Cure and Care of Dementia)), Dementia Narrative (Qualitative Research), Dementia Research, Dementia-Friendly Communities, Dementia-Friendly Design, Dementia-Friendly Products, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Disproportionate Burden of Dementia on Women, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, Emerging Leaders In Dementia (aka Young Leaders in Dementia), Experiences, First Global Ministerial Conference on Global Action Against Dementia, First WHO Ministerial Conference on Global Action Against Dementia, G7 Countries, G7 Dementia Summit, G7 Global Dementia Summit, G8 Dementia Summit, G8 Dementia Summit: Global Action Against Dementia, GAAD: Global Action Against Dementia, Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Dementia Framework, Global Ministerial Conference on Global Action Against Dementia (WHO), Global Outlook, Global Toolbox for Dementia Research (Proposal), Government Research Funding, Group of 7 (G7), Home Care Standards, Intergenerational Cohesion, Intergenerational Mingling, Intergenerational Relations, Intergenerational Solidarity, Intergenerational Work, International Collaborations, International Dementia-Friendly Symbol (Proposal), International Programmes, Interventions: Outcomes and Cost Savings, Knowledge Translation, Leadership, Lived Experience, London, Mobile Technology, Multi-Generational Approaches, Multisectoral Collaboration, OECD, One-Stop Shops, Organisation for Economic Co-operation and Development (OECD), Organisation for Economic Co-operation and Development (OECD) Countries, Ottawa, Outcomes and Monitoring, Outcomes Benchmarking, Partnership, Partnership and Collaboration, Partnership Working, Patient Experience, Personal Experience of Dementia, Prevalence of Dementia, Prevention, Prevention Programmes, Prime Minister’s Dementia Challenge, Purple Angel Logo, Quality of Care, Quality of Care and Support, Quality of Care for People With Dementia, Reducing Stigma, Research and Development, Research and Innovation, Research Commitment, Research Funding, Science and Innovation Network (SIN), Service User Experience, Social Care Standards, Stigma, Stigma of Dementia, Stigma-Free Environments, Tokyo, UK Science and Innovation Network, UK Science and Innovation Network (SIN), Voluntary and SME Sectors, Washington DC, Working With Professionals From Other Sectors, World Health Organisation (WHO), World Health Organisation (WHO) Regional Office for Europe, Young Leaders in Dementia (#YLDementia), Young Leaders in Dementia (Canada Japan USA Europe), Young Leaders in Dementia Group
|
Leave a comment
Global Ministerial Conference on Global Action Against Dementia (WHO / Department of Health / Dementia Challenge)
Summary The World Health Organisation (WHO) will stage the First Global Ministerial Conference on Global Action Against Dementia on March 16th – 17th 2015, in Geneva. This event will engage a larger number of countries in the international focus on … Continue reading →
Posted in Acute Hospitals, Commissioning, Community Care, Dementia Care Pathway Group, Department of Health, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Northern Ireland, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, Statistics, UK, Universal Interest, World Health Organization (WHO)
|
Tagged Ageing and Dementia, Ageing and Society, Ageing Population, Awareness Raising, Burden of Dementia, Challenge on Dementia (David Cameron), Collaboration, Collaborative Projects, Cross-Sector Partnerships, Dementia Alliance International, Dementia Challenge, Dementia Diagnosis, Dementia Research, Department of Health's Digital Health Blog, Digital Engagement, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Margaret Chan: WHO Director-General, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, First Global Ministerial Conference on Global Action Against Dementia, G8 Dementia Summit, G8 Dementia Summit: Global Action Against Dementia, Global Action Against Dementia, Global Ministerial Conference on Global Action Against Dementia (WHO), Global Outlook, Government Research Funding, Human Rights, International Collaborations, International Programmes, Kate Swaffer: Chair of Dementia Alliance International, Knowledge Translation, Leadership, OECD, Organisation for Economic Co-operation and Development (OECD), Organisation for Economic Co-operation and Development (OECD) Countries, Partnership, Partnership and Collaboration, Partnership Working, Prescribed Disengagement, Prevalence of Dementia, Prevention, Prevention Programmes, Prime Minister’s Dementia Challenge, Quality of Care, Quality of Care and Support, Quality of Care for People With Dementia, Reducing Stigma, Rehabilitation in Dementia, Research and Development, Research and Innovation, Research Commitment, Research Funding, World Health Organisation (WHO), World Health Organisation (WHO) Regional Office for Europe
|
Leave a comment
UK-Based Drug Discovery Alliance (BBC News / Alzheimer’s Research UK)
Summary Alzheimer’s Research UK has announced the launch of the Drug Discovery Alliance, a £30 million network of research centres working collaboratively on research to discover potential cures, or at least disease modifying treatments, for Alzheimer’s Disease and other forms … Continue reading →
Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, For Researchers (mostly), In the News, National, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Academia-Industry Partnerships, Academia-Industry Synergies, Alzheimer’s Research UK Drug Discovery Institute, Alzheimer’s Research UK’s Drug Discovery Alliance, Big Pharma, Cambridge Biomedical Campus, Cambridge Drug Discovery Institute, Cambridge University, Clinical Research Networks, Collaborative Drug Discovery Programmes, Commissioning Research, Crowd-Sourced Information, Crowdsourcing, Dementia Research, Dementia Research Priorities, Dementia Research: UK Impact, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Eric Karran: Director of Research at Alzheimer’s Research UK, Dr Laura Phipps: Alzheimer’s Research UK, Drug Discovery Alliance, Drug Discovery Institute, Drug Discovery Institutes, Drug Discovery Programmes, Drugs for Treatment of Alzheimer’s Disease, Experimental Alzheimer's Drugs, First G8 Dementia Summit, G8 Dementia Summit, Genetic Research, Genetic Triggers, Global Action Against Dementia, Global Clinical Development Fund, Global Context, Global Dementia Legacy Event, Global Leadership, Global Outlook, Gurdon Institute: University of Cambridge, Innovation in Genetics, International Collaborations, International Organisations, International Programmes, Knowledge Networks, Knowledge Translation, Medical Research, MIT Sloan School of Management: Model for Public-Private Partnerships in Funding Research, Multidisciplinary Research Teams, Networks, Networks and Alliances, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Oxford Drug Discovery Institute, Oxford University, Parallel Discovery of Alzheimer’s Therapeutics (MIT Sloan and University of California Model), Partnership, Partnership and Collaboration, Partnership Working, Payment Systems and Incentives, Pharmacological Research, Philanthropic Funding, Philanthropy, Prof. David Rubinsztein: Lead Academic Scientist at Cambridge Drug Discovery Institute, Prof. Giampietro Schiavo: Co-Lead Academic Scientist at UCL Drug Discovery Institute, Prof; Simon Lovestone: Co-Lead Academic Scientists at Oxford Drug Discovery Institute, Research Commitment, Research Consortia, Research Culture, Research Mapping, Research Networks, Research Programmes, Scientific Management Board of the Drug Discovery Institute, Stem Cell Research, Translational Research, UCL Drug Discovery Institute, University College London (UCL), University of Cambridge, University of Oxford
|
Leave a comment
Second Global Dementia Legacy Event: Ottawa, September 11th/12th 2014 (Department of Health / Dementia Challenge / World Dementia Council / CIHR / AVIESAN)
Summary Canada and France are co-hosting the second Global Action Against Dementia Legacy Event in Ottawa (Canada) on September 11th – 12th 2014. This event will explore how to take advantage of partnership working and collaboration between industry and academia, … Continue reading →
Posted in Acute Hospitals, Community Care, Department of Health, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, Universal Interest
|
Tagged Academia-Industry Partnerships, Academia-Industry Synergies, Academic-Industry Collaborations, Alain Beaudet: President of Canadian Institutes of Health Research (CIHR), Alice Wong: Minister of State (Seniors) in Canada, Alzheimer Society of Canada, AVIESAN: French National Alliance for Life Sciences and Health, •Alzheimer Society of Canada, Big Data, Biotechnology, Canada, Canada's Research Strategy for Alzheimer's Disease, Canada-France Legacy Event, Canadian Institutes of Health Research (CIHR), Challenge on Dementia, Challenge on Dementia (David Cameron), Collaboration, Collaborative Projects, Cross-Sector Partnerships, Dementia Challenge, Dementia in Canada, Dementia Innovation, Dementia Research, Dementia Time-Bomb, Dennis Gillings: Former World Dementia Envoy, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programme, Drug Identification, Drug-Development Pipeline, Faye Forbes (Living With Dementia), France, Free Open Access Journals, G7 Global Dementia Summit, G8 Dementia Summit, G8 Dementia Summit Agreements, G8 Summit on Dementia Communique, G8 Summit on Dementia Declaration, Global Action Against Dementia, Global Context, Global Dementia Legacy Event, Global Dementia Legacy Event on Academia-Industry Synergies, Global Leadership, Global Outlook, Incentives and Investment, Incentives for Drug Development, Innovation, Innovative Medicines Initiative, Institute of Health and Medical Research (Inserm), International Collaborations, International Programmes, Japan Legacy Event, Knowledge Networks, Knowledge Translation, Massachusetts Biotech Cluster: CONNECT, Matthew Dineen (Carer), Medical Devices, Networks, Networks and Alliances, Neurological Research, OECD Big Data and Sustainability Initiative for Large-Scale Research on Dementia, Open Access, Open Access Databases, Open Access Journals, Open Access Knowledge Resources, Open Access Research, Partnership, Partnership and Collaboration, Partnership Working, Payment Systems and Incentives, Pharmaceutical Industry, Pharmacological Research, Philippe Zeller: Ambassador of France to Canada, Prime Minister's Challenge on Dementia, Prime Minister’s Dementia Challenge, Regulatory Barriers: Regulatory Environment, Removing Regulatory Barriers, Research and Innovation, Research Networks, Resource and Incentives, Second Global Dementia Legacy Event, Second Global Dementia Legacy Event (Ottawa: September 2014), The Honourable Rona Ambrose: Minister of Health (Canada), UK Legacy Event, USA Legacy Event, Venture Capital (Approach to Research), World Dementia Council, Yves Lévy: French National Institute of Health and Medical Research (Inserm) and Chairman of Aviesan (French National Alliance for Life Sciences and Health Care)
|
Leave a comment
UK Genomes Project: Genomics England (BBC News / NHS England / HEE / Nature Genetics)
Summary A revolution in medicine is in progress at research centres across the UK, based on unlocking the genetic bases of cancer and other diseases. The UK could become a world leader in genetic research, targeted therapies and personalised medicine. … Continue reading →
Posted in BBC News, Department of Health, Health Education England (HEE), In the News, International, National, NHS, NHS England, Personalisation, Quick Insights, UK, Universal Interest
|
Tagged 100000 Genome Project: NHS Genomic Medicine Centres, 100000 Genomes Project, Aarhus University, Akureyri Hospital (Iceland), Astra Zeneca, BBC Health News, Bioinformatics Research Centre: Aarhus University, Biological Treatments, Biotechnology Companies, Birmingham, Broad Institute / Whitehead Institute (Massachusetts), Bubble-Boy Syndrome (Immune Disorders), Call for Global Moratorium on Clinical Uses of Human Germline Editing, Cambridge, Cambridge University Hospitals NHS Foundation Trust: Genomics Medicines Centre, Cancer Research UK (CRUK), Cas9 (Crispr-Associated Protein 9) Enzyme, Cell and Gene Therapy at Institute of Child Health (ICH), Central Manchester University Hospitals NHS Foundation Trust: Genomics Medicines Centre, Chief Scientific Officer Bulletin, Chief Scientific Officer Bulletin (July 2014), Children's Hospital: Landspitali University Hospital (Reykjavik Iceland), Cleveland Clinic, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Collaborative Projects, Collaborative Working, Crispr, Crispr-Cas9, CRISPR-Cas9 Genome Editing System, Crisprs (Clustered Regularly Interspaced Short Palindromic Repeats), Cross-Sector Partnerships, David Cameron, deCODE Genetics, deCODE Genetics /Amgen Inc., Decoding Inherited Disorders, Dementia Research, Denmark, Department of Human Genetics: University of Leuven, Department of Internal Medicine: Akureyri Hospital (Iceland), Dilated Cardiomyopathy, Division of Cardiovascular Diseases: Mayo Clinic, DNA Extraction, Dr Francis Collins: Director of National Institutes of Health (USA), Dr Marcy Darnovsky: Center for Genetics and Society (USA), Drugs Targeted at Specific Mutations, Duke University, East Anglian Medical Genetics Service: Cambridge University Hospitals NHS Foundation Trust, East of England, East of England NHS GMC: Cambridge University Hospitals NHS Foundation Trust, Elimination of Porcine Endogenous Retroviruses Using Crispr, Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center, Ethical Considerations, Ethical Dilemmas, European Bioinformatics Institute, European Bioinformatics Institute: Wellcome Trust Genome Campus, Exeter, Familial Adenomatous Polyposis (FAP), Foetal Stem Cells, Four Ps of Personalised Medicine: Participatory Role for Patients, Four Ps of Personalised Medicine: Precise Diagnoses, Four Ps of Personalised Medicine: Prediction and Prevention of Disease, Four Ps of Personalised Medicine: Targeted and Personalised Interventions, Francis Crick Institute, Fred and Pamela Buffett Cancer Centre (Omaha), Gene Editing in Mice With Duchenne Muscular Dystrophy, Genetic Disorders and Genomics, Genetic Engineering (Pandora's Box), Genetic Modification of Cells: HIV Treatment Strategy, Genetic Profiling, Genetic Research, Genetic Susceptibility Loci, Genetic Triggers, Genetic Variants, Genetics of Alzheimer's Disease, Genome Campus (Wellcome Trust), Genome Sequencing, Genomic Computing, Genomic Medicine, Genomic Medicine Centres, Genomic Medicine Centres (GMCs), Genomics, Genomics Education Programme, Genomics Education Programme (HEE), Genomics England, Genomics England’s Ethics Advisory Committee, Genomics in the NHS, Genomics-Based Medicine, Genotyping, Germline Alterations (Suggested for DMD Huntington's Disease or Cystic Fibrosis), Germline Editing, Germline Gene Editing, Germline Modification, GM Babies, Great Ormond Street Hospital, Great Ormond Street Hospital (GOSH), Great Ormond Street Hospital NHS Foundation Trust: Genomics Medicines Centre, Greater Manchester, Greater Manchester NHS GMC: Central Manchester University Hospitals NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust: Genomics Medicines Centre London, Harvard University, Health Education England's Genomics Education Programme, HEE: Health Education England, Herceptin, Heritable Human Genome Editing (HHGE), Hinxton Group, Housekeeping Proteins, Human Embryos Edited (August 2017), Human Genetic Disorders, Human Germline Editing, Human Germline Genome Editing (HGGE), Human Protein Atlas, Hypertrophic Cardiomyopathy, IBM Watson Health, IBM's Watson Supercomputer, Iceland, Icelandic Medical Center (Laeknasetrid), IL2RG Gene, Illumina, Imperial College Health Partners NHS GMC: Imperial College Healthcare NHS Trust, Imperial College Healthcare NHS Trust: Genomics Medicines Centre, Improved Prevention Based on Underlying Predisposition, In Utero Stem Cell Therapy, Innovation in Biotechnology, Innovation in Genetics, Innovative Genomics Initiative (University of California in Berkeley / University of California in San Francisco), Institute of Child Health (ICH), International Commission on the Clinical Use of Human Germline Genome Editing, International Summit on Human Gene Editing, Introducing Genomics in Healthcare (Health Education England Video), Knowledge Networks, Knowledge Translation, Knut & Alice Wallenberg Foundation, Knut and Alice Wallenberg Foundation, Laboratory in Mjodd (RAM) Iceland, Landscape of Mutations in Breast Cancer Whole-Genome Sequences, Landspitali University Hospital (Iceland), Large DNA Banks, Large-Scale Whole-Genome Sequencing, Large-Scale Whole-Genome Sequencing (Iceland), Liverpool Women's NHS Foundation Trust: Genomics Medicines Centre, London, Lund University, Mayo Clinic (Rochester Minnesota), McDonnell Genome Institute: Washington University (St. Louis), Medical Director of NHS England: Professor Sir Bruce Keogh, Medical Research Council (MRC), Microarrays, Moratorium on Heritable Genome Editing, Mutational Signatures, Mutational Signatures in Breast Cancer, Networks, Networks and Alliances, Newcastle upon Tyne Hospitals NHS Foundation Trust: Genomics Medicines Centre, Next-Generation Sequencing (NGS), NHS Genomic Medicine Centres, NHS Genomic Medicine Centres (NHS GMCs), NHS Genomic Medicine Centres Prospectus, NHS Genomics Medicine Centres, NHS Workforce, North East, North East and North Cumbria NHS GMC: Newcastle upon Tyne Hospitals NHS Foundation Trust, North Thames Genomic Medicine Centre, North Thames NHS Genomic Medicine Centre (NHS GMC), North West Coast NHS GMC: Liverpool Women’s NHS Foundation Trust, North West London Healthcare Trust, Nuffield Council on Bioethics, OHSU Knight Cardiovascular Institute, Osteogenesis Imperfecta, Oxford, Oxford NHS GMC: Oxford University Hospitals Foundation Trust, Oxford University Hospitals Foundation Trust: Genomics Medicines Centre, Partnership, Partnership and Collaboration, Partnership Working, Personalised Health Care for Cancer, Personalised Medicine, Personalised Medicine Strategy (NHS England), Personalised Medicine Strategy Board, Personalised Medicine Strategy for the NHS, Personalised Medicine: Improving Outcomes, Peter Grainger: Patient and Public Involvement Representative at St Mark’s Hospital (North West London Healthcare Trust), Pharmaceutical Industry, PHG Foundation, Prof Peter Braude: King's College London, Professor Ian Cumming OBE: HEE Chief Executive, Professor Sir Bruce Keogh, Professor Sue Hill: Chief Scientific Officer for England, Profiling Individual Cancer Genomes (Personalised Medicine), Protein-Coding Cancer Genes, Radboud University, Regional Genetic Laboratories, Research and Development, Research and Innovation, Research Commitment, Research Consortia, Research Culture, Research Into Aging, Research Networks, Researcher Access to Data, Resources for Researchers, Royal Devon and Exeter NHS Foundation Trust: Genomics Medicines Centre, Royal Institute of Technology in Sweden, Sanger Institute, School of Engineering and Natural Sciences, Science Working Group: Cancer, Science Working Group: Infectious Diseases, Science Working Group: Rare Diseases, Small and Medium Enterprises (SMEs), SMEs, Somatic Genetic Basis of Breast Cancer, South London NHS GMC: Guy’s and St Thomas’ NHS Foundation Trust, South West Peninsula, South West Peninsula NHS GMC: Royal Devon and Exeter NHS Foundation Trust, Southampton, St Mark’s Hospital, Sun Yat-sen University in Guangdong (China), Talens, Targeted Drugs, Targeted Therapies, Testes, Thermo Fisher Scientific (Massachusetts), Transformational Elements of NHS Genomic Medicine Centres, UK Genomes Project: Genomics England, UK Research and Life Science Sector, University College London Partners NHS GMC: Great Ormond Street Hospital NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust: Genomics Medicines Centre, University Hospitals Birmingham NHS Foundation Trust: Genomics Medicines Centre, University of Iceland, University of Texas MD Anderson Cancer Center, USA, Viv Parry OBE (Science Broadcaster), Wellcome Trust, Wellcome Trust Sanger Institute, Wessex NHS GMC: University Hospital Southampton NHS Foundation Trust, West Midlands, West Midlands NHS GMC: University Hospitals Birmingham NHS Foundation Trust, Whole Genome Sequencing, Workforce Competencies, Workforce Development, Workforce Training, Xenotransplantation: Avoiding Shortage of Human Donor Organs, Yale Cancer Centre, Zinc fingers
|
Leave a comment
Defeat Dementia Campaign (Alzheimer’s Research UK)
Summary Alzheimer’s Research UK’s “Defeat Dementia” campaign was announced at the Global Dementia Legacy Event on June 19th 2014. Commitments included in the Defeat Dementia programme include: The launch of the Alzheimer’s Research UK Stem Cell Research Centre. There is a £2 … Continue reading →
Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, Diagnosis, For Carers (mostly), For Researchers (mostly), In the News, Management of Condition, Quick Insights, UK, Universal Interest
|
Tagged Alzheimer’s Research UK Stem Cell Research Centre, Charitable Funding, Collaborative Projects, Cross-Sector Partnerships, Defeat Dementia Campaign, Defeat Dementia Campaign (Alzheimer’s Research UK), Dementia Challenge, Dementia Diagnosis, Dementia Innovation, Dementia Research, Dementia Research: UK Impact, Drug Discovery Institutes, G8 Dementia Summit, Genetic Research, Genetic Triggers, Global Action Against Dementia, Global Clinical Development Fund, Global Context, Global Dementia Legacy Event, Global Leadership, Global Outlook, Gurdon Institute: University of Cambridge, Innovation in Genetics, Knowledge Networks, Knowledge Translation, Networks, Networks and Alliances, Partnership, Partnership and Collaboration, Partnership Working, Payment Systems and Incentives, Philanthropic Funding, Philanthropy, Research Networks, Stem Cell Research, Stem Cell Research Centre, Translational Research, University College London, University of Cambridge
|
Leave a comment
